Cynata Therapeutics Ltd (ASX: CYP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cynata Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cynata Therapeutics Ltd (ASX: CYP)
Latest News
Share Market News
Federal Court approves Sirtex Medical Limited (ASX:SRX) takeover: Where I would reinvest these funds
Share Gainers
These 3 small cap shares are on the rise on Monday
Share Gainers
3 small-cap healthcare shares I think could be tomorrow's blue chips
Healthcare Shares
3 small cap healthcare shares on my watchlist
Healthcare Shares
3 small cap healthcare shares to watch
⏸️ Investing
Why these 3 small cap shares are zooming higher
⏸️ Investing
Are these the next ASX biotech stars?
⏸️ Investing
Why these 4 ASX shares climbed higher today
⏸️ Investing
10 exciting small cap shares to watch
⏸️ Investing
Why these 4 ASX shares sank lower today
⏸️ Investing
Why these 4 ASX shares are ending the week on a high
⏸️ Investing
3 healthcare shares delivering big returns
CYP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Cynata Therapeutics Ltd
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinicaltrials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
CYP Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
24 Apr 2024 | $0.21 | $0.01 | 5.00% | 227,966 | $0.20 | $0.21 | $0.19 |
23 Apr 2024 | $0.20 | $-0.01 | -4.76% | 50,193 | $0.20 | $0.20 | $0.20 |
22 Apr 2024 | $0.21 | $0.00 | 0.00% | 120,203 | $0.21 | $0.21 | $0.21 |
19 Apr 2024 | $0.21 | $0.00 | 0.00% | 154,215 | $0.21 | $0.22 | $0.21 |
18 Apr 2024 | $0.21 | $0.01 | 4.88% | 79,012 | $0.21 | $0.21 | $0.21 |
17 Apr 2024 | $0.21 | $-0.01 | -4.76% | 78,547 | $0.21 | $0.21 | $0.20 |
16 Apr 2024 | $0.21 | $0.01 | 4.88% | 380,973 | $0.21 | $0.21 | $0.20 |
15 Apr 2024 | $0.21 | $0.02 | 10.81% | 366,096 | $0.19 | $0.22 | $0.19 |
12 Apr 2024 | $0.19 | $0.00 | 0.00% | 17,003 | $0.19 | $0.19 | $0.19 |
11 Apr 2024 | $0.19 | $0.00 | 0.00% | 4,590 | $0.19 | $0.19 | $0.19 |
10 Apr 2024 | $0.19 | $0.01 | 5.56% | 64,557 | $0.18 | $0.19 | $0.18 |
09 Apr 2024 | $0.18 | $0.00 | 0.00% | 53,693 | $0.18 | $0.18 | $0.18 |
08 Apr 2024 | $0.18 | $-0.02 | -10.26% | 614,740 | $0.19 | $0.19 | $0.18 |
05 Apr 2024 | $0.20 | $-0.01 | -5.00% | 51,197 | $0.20 | $0.20 | $0.19 |
04 Apr 2024 | $0.20 | $0.02 | 10.81% | 285,076 | $0.18 | $0.20 | $0.18 |
03 Apr 2024 | $0.19 | $0.00 | 0.00% | 215,050 | $0.19 | $0.19 | $0.18 |
02 Apr 2024 | $0.19 | $-0.01 | -5.26% | 86,638 | $0.18 | $0.19 | $0.18 |
28 Mar 2024 | $0.19 | $0.02 | 11.43% | 41,946 | $0.19 | $0.19 | $0.19 |
27 Mar 2024 | $0.18 | $-0.02 | -10.53% | 82,882 | $0.18 | $0.19 | $0.18 |
26 Mar 2024 | $0.19 | $0.02 | 11.43% | 91,135 | $0.18 | $0.19 | $0.18 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
22 Nov 2023 | Kilian Kelly | Buy | 94,143 | $12,439 |
On-market trade.
|
20 Nov 2023 | Darryl Maher | Issued | 220,000 | $26,400 |
Issue of options.
|
20 Nov 2023 | Kilian Kelly | Issued | 750,000 | $90,000 |
Issue of options.
|
20 Nov 2023 | Janine Rolfe | Issued | 220,000 | $26,400 |
Issue of options.
|
20 Nov 2023 | Paul Wotton | Issued | 220,000 | $26,400 |
Issue of options.
|
20 Nov 2023 | Geoffrey Brooke | Issued | 500,000 | $60,000 |
Issue of options.
|
01 Jun 2023 | Stewart Washer | Issued | 69,767 | $9,418 |
Issue of options.
|
01 Jun 2023 | Stewart Washer | Issued | 139,534 | $29,999 |
Placement.
|
01 Jun 2023 | Janine Rolfe | Issued | 58,140 | $7,848 |
Issue of options.
|
01 Jun 2023 | Janine Rolfe | Issued | 116,279 | $24,999 |
Placement.
|
01 Jun 2023 | Ross Macdonald | Issued | 55,813 | $11,999 |
Placement.
|
01 Jun 2023 | Ross Macdonald | Issued | 27,907 | $3,767 |
Issue of options.
|
01 Jun 2023 | Geoffrey Brooke | Issued | 69,767 | $9,418 |
Issue of options.
|
01 Jun 2023 | Geoffrey Brooke | Issued | 139,534 | $29,999 |
Placement.
|
01 Jun 2023 | Darryl Maher | Issued | 50,000 | $10,750 |
Placement.
|
01 Jun 2023 | Darryl Maher | Issued | 25,000 | $3,375 |
Issue of options.
|
01 Jun 2023 | Paul Wotton | Issued | 69,767 | $9,418 |
Issue of options.
|
01 Jun 2023 | Paul Wotton | Issued | 139,534 | $29,999 |
Placement.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Paul K Wotton | Non-Executive Director | Jun 2016 |
Mr Wotton has joined the Board in June 2016 and was Non-Executive Chair from 28 February 2017 until 18 August 2020. Dr Wotton was the Chief Executive Officer of Obsidian Therapeutics, a clinical stage TIL therapy company based in Cambridge, Massachusetts. Prior to this, he was the Founding President and CEO of Sigilon Inc. Prior to joining Antares, Dr Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Dr Wotton held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr Wotton is a member of the Board and Governance Committee of Vericel Corporation (NASDQA: VCEL), a US company developing autologous cellular therapies, Chairman of Kytopen Corp., an MIT startup focused on non-viral transduction technology, independent director at Dimension Inx, a biomaterials platform company and Founder of AvengeBio, a clinical stage immune oncology company focused on ovarian and peritoneal cancers. He was a member of the board of Veloxis Pharmaceuticals AS and Chairman of the Compensation Committee, until its acquisition by Asahi Kasai in February 2020 in a $1.3 billion all cash transaction. He is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. In 2014, he was named New Jersey EY Entrepreneur of the Year in Life Sciences.
|
Mr Peter Webse | Company Secretary | May 2012 |
Mr Webse has over 28 years company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services.
|
Dr Geoffrey E.D Brooke | Non-Executive DirectorNon-Executive Chairman | May 2019 |
Mr Brooke has joined the Board in May 2019 as Non-Executive Director and appointed Chair on 18 August 2020.Dr Brooke co-founded GBS Venture Partners in 1996 and has more than 30 years' venture capital experience. He was formerly President of Medvest Inc.a US-based early stage venture capital group he founded with Johnson & Johnson.Dr Brooke's experience includes company formation and acquisitions as well as public listings on NYSE, NASDAQ and ASX exchanges. From 2009 until 2015,Dr Brooke was an independent director of the Victoria Workcover Authority.
|
Mrs Janine Rolfe | Non-Executive Director | Sep 2022 |
Ms Rolfe joined the Board in September 2022. Ms Rolfe brings more than two decades of legal, governance and management experience across various sectors to the Board. In recent years, Ms Rolfe has transitioned to professional non-executive director roles. Ms Rolfe's last executive role was as General Counsel & Company Secretary for S&P/ASX100 Link Group. Prior to that, Ms Rolfe established governance consultancy, Company Matters, where she served at the helm for over a decade and during a period where stakeholders greatly intensified their expectations of Australian companies' governance practices. Previously, she was a legal counsel and company secretary at Qantas Airways and a solicitor at Mallesons Stephen Jaques (now King & Wood Mallesons).
|
Dr Darryl Maher | Non-Executive Director | Jun 2020 |
Mr Maher has joined the Board in June 2020. Dr Maher adds global biopharmaceutical and commercialisation capability to the Cynata board, with over 23 years' experience with CSL Limited. CSL is one of the developers of biologic pharmaceutical products and has a market capitalisation of A$130 billion. Dr Maher has had career in pharmaceutical product development, most recently as the former Vice President of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the development of drug products from initiation through to clinical development and to commercialisation. Dr Maher undertook medical training, qualified as a specialist haematologist.
|
Dr Kilian Kelly | Chief Executive OfficerManaging Director | Jul 2023 |
--
|
Dr Jolanta Airey | Chief Medical Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Phillip Asset Management Limited <Bioscience MTF1 AC> | 23,588,040 | 13.13% |
HSBC Custody Nominees Australia Limited | 17,172,745 | 9.56% |
Citicorp Nominees Pty Limited | 8,692,216 | 4.84% |
Fujifilm Corporation | 8,088,403 | 4.50% |
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> | 4,248,421 | 2.37% |
BNP Paribas Nominees Pty Ltd Acf Clearstream | 2,730,212 | 1.52% |
National Nominees Limited | 2,500,000 | 1.39% |
HSBC Custody Nominees Australia Limited GSCO ECA | 2,012,007 | 1.12% |
Dr Ross Alexander Macdonald | 2,000,000 | 1.11% |
Bnp Paribas Noms Pty Ltd <Drp> | 1,702,710 | 0.95% |
Mal Washer Nominees Pty Ltd <Mal Washer Family A/C> | 1,559,534 | 0.87% |
Mr Pawel Rej & Mrs Miroslawa Rej | 1,543,036 | 0.86% |
Mr David Charles Prodrick | 1,500,000 | 0.84% |
Crosswind Trustee Company Limited <Crosswind A/C> | 1,500,000 | 0.84% |
Mr Patrick Anthony Walsh | 1,341,790 | 0.75% |
Mr Jon Nicolai Bjarnason & Mrs Rina Eghoje Bjarnason <Jarck Super Fund A/C> | 1,200,000 | 0.67% |
Dr Maksym Vodyanyk | 1,191,658 | 0.66% |
Helium Management Pty Ltd <Helium SF A/C> | 1,135,366 | 0.63% |
Mr Craig Lawrence Darby | 1,110,066 | 0.62% |
LFT Co 2018 Pty Ltd <Lenz Family A> | 1,080,000 | 0.60% |